Mild cognitive impairment (MCI) refers to mild memory loss and loss of cognitive ability. It affects more than 700,000 people across Canada. Our study is investigating the effects of psilocybin on the brain activity of individuals living with MCI in order to explore psilocybin as a potential future treatment for this condition. We are recruiting participants who are currently experiencing problems with their thinking abilities (e.g., memory, concentration). We are also recruiting healthy adults who do not have cognitive impairment. All participants must be at least 60 years old.
Participation will include a screening process, neuropsychological testing, magnetic resonance imaging (MRI) scans, positron emission tomography (PET) scans, and either psilocybin treatments or placebo treatments.
The study will consist of 9 visits across 12 weeks, for a total of about 41 hours. You will be compensated for your time.
- Visit 1: Screening (about 2-3 hours)
- Visit 2: Neuropsychological testing (about 2-3 hours)
- Visit 3: MRI Scan (about 1 hour)
- Visits 4 and 7: PET Scans (about 2-3 hours)
- Visit 5 and 6: Psilocybin or placebo treatment (about 7 hours/visit)
- Visit 8 and 9: Follow-up (about 3-4 hours)
To learn more or ask about joining our study, contact us:
- Email: MMIGResearch@camh.ca
- Phone: (416) 535-8501 ext 30622
The security of information sent by e-mail cannot be guaranteed. Please do not communicate personal sensitive information by e-mail.
Additional study details available in our CAMH study listing: CAMH REB number: 101/2021
For information about programs and services at CAMH, please click here or call 416-535-8501 (or 1-800-463-6273).